<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00032942</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-CSP-1020-1</org_study_id>
    <nct_id>NCT00032942</nct_id>
    <nct_alias>NCT00007566</nct_alias>
    <nct_alias>NCT00024713</nct_alias>
  </id_info>
  <brief_title>Lofexidine for Opiate Withdrawal - 1</brief_title>
  <official_title>A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Britannia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate lofexidine for opiate withdrawal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An 11 day inpatient placebo-controlled, double-blind study of 96 opiate dependent, treatment
      seeking individuals randomized to 2 medication groups: lofexidine and placebo to be conducted
      in inpatient units at 3 treatment sites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opiate withdrawal symptoms</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential Abuse Liability</measure>
  </primary_outcome>
  <enrollment>66</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female as least 18 yrs of age &amp; above with a current dependence on heroin, morphine
        or hydromorphone according to DSM4 criteria; subject ; voluntarily given consent and signed
        informed consent; females using appropriate birth control method.

        Exclusion Criteria:

        Additional criteria available during screening at the site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Montgomery, R.N.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Drug Abuse (NIDA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Veterans Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2002</study_first_submitted>
  <study_first_submitted_qc>April 5, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2002</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <name_title>Ann Montgomery</name_title>
    <organization>National Institute on Drug about</organization>
  </responsible_party>
  <keyword>opiate dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opiate Alkaloids</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Lofexidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

